CN EN JP
{pboot:sort scode=} [sort:name]
[sort:name]
{/pboot:sort}
{pboot:sort scode=}[sort:name]{/pboot:sort}
2025.06.19ZonhonBio's ZHB111 Injection Receives FDA Approval for Phase I Clinical Trial
ON June 18, 2025, ZonhonBio announced today that the U.S. FDA has approved its Investigationa···
2025.06.18Phase I Clinical Trial Application for Anti-Allergy Desensitization Drug ZHB118 Sublingual Tablets Approved by NMPA
On June 17th, 2025, ZonhonBio's innovative Class 1 biologic drug ZHB118 sublingual tablets, inde···
2025.05.16Phase I Clinical Trial Officially Launched for CNS Drug ZHB601 for Injection
On May 15th, 2025, the Phase I clinical trial for ZHB601 for Injection - a Class I new chemical drug···
2025.05.05New Targeted Anti-Cancer Drug ZHB114 for Injection Granted New Indication Approval by U.S. FDA
On May 2nd, 2025, the Investigational New Drug (IND) application for ZHB114 for Injection—a Class I ···
2025.03.25Phase I Clinical Trial Application of Anti-Allergy Desensitization Drug ZHB117 Sublingual Tablets Approved by the NMPA
On March 24th, 2025, Zonhonbio's independently developed Class I new biologic drug—ZHB117 sublin···
2025.02.15Phase I Clinical Trial Officially Launched of Anti-Allergy Desensitization Drug ZHB110 Sublingual Tablets
On February 14th, 2025, the Phase I clinical trial for ZHB110 sublingual tablets—a Class 1 new biolo···
2025.01.27Phase I Clinical Trial Application of Central Nervous System Drug ZHB601 for Injection Approved by the NMPA
On January 26th, 2025, Zonhonbio's Class I new chemical drug—ZHB601 for Injection received the &···
2025.01.25The 2024 Annual Meeting and 2025 New Year Party os Zonhonbio and Gensunbio Held Successfully
Auspicious dragon ushers in achievement, and golden serpent welcomes a new journey. On January 22, 2···